Commercial molecular panels are of limited utility in the classification of pancreatic cystic lesions

American Journal of Surgical Pathology

Volumn 36, Issue 10, 2012, Pages 1434-1443

  Panarelli, Nicole C ^a   Sela, Raanan ^a   Schreiner, Andrew M ^a   Crapanzano, John P ^b   Klimstra, David S ^c   Schnoll Sussman, Felice ^a   Pochapin, Mark B ^a   Yantiss, Rhonda K ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

endoscopic ultrasound; fine needle aspiration biopsy; mucinous; pancreas; PathfinderTG; Redpath Integrated Pathology

Indexed keywords

DNA; KRAS PROTEIN, HUMAN; MICROSATELLITE DNA; MUCIN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; CLASSIFICATION; CYSTADENOMA; DIFFERENTIAL DIAGNOSIS; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEUROENDOCRINE TUMOR; PANCREAS CYST; PANCREAS PSEUDOCYST; PANCREAS TUMOR; PROSPECTIVE STUDY;

ADULT; AGED; ALLELIC IMBALANCE; CYSTADENOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; FEMALE; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUCINS; NEUROENDOCRINE TUMORS; PANCREATIC CYST; PANCREATIC NEOPLASMS; PANCREATIC PSEUDOCYST; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866633295     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31825d534a     Document Type: Article

References (34)

1. Afify AM, al-Khafaji BM, Kim B, et al. Endoscopic ultrasound-guided fine needle aspiration of the pancreas. Diagnostic utility and accuracy. Acta Cytol. 2003;47:341-348.
2. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6: 17-32.
3. Turner BG, Brugge WR. Pancreatic cystic lesions: when to watch, when to operate, and when to ignore. Curr Gastroenterol Rep. 2010;12:98-105.
4. Pitman MB, Genevay M, Yaeger K, et al. High-grade atypical epithelial cells in pancreatic mucinous cysts are a more accurate predictor of malignancy than "positive" cytology. Cancer Cytopathol. 2010;118:434-440.
5. Schoedel KE, Finkelstein SD, Ohori NP. KRAS and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Diagn Cytopathol. 2006;34: 605-608.
6. Hruban RH, Pitman MB, Klimstra DS. Endocrine neoplasms. In: Silverberg SG, Sobin LH, eds. Tumors of the Pancreas AFIP Atlas Series 4. Washington, DC: ARP Press; 2007:251-304.
7. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977-987.
8. Michaels P, Brachtel EF, Bounds BC, et al. Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade. Cancer. 2006;108:163-173.
9. Recine M, Kaw M, Evans DB, et al. Fine-needle aspiration cytology of mucinous tumors of the pancreas. Cancer Cytopathol. 2004;102: 92-99.
10. Khalid A, Pal R, Sasatomi E, et al. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreatobiliary malignancy from brush cytology samples. Gut. 2004;53:1860-1865.
11. Khalid A, McGrath KM, Zahid M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastro-enterol Hepatol. 2005;3:967-973.
12. Bentz JS, Kochman ML, Faigel DO, et al. Endoscopic ultrasound-guided real-time fine-needle aspiration: clinicopathologic features of 60 patients. Diagn Cytopathol. 1998;18:98-109.
13. Stelow EB, Bardales RH, Stanley MW. Pitfalls in endoscopic ultrasound-guided fine-needle aspiration and how to avoid them. Adv Anat Pathol. 2005;12:62-73.
14. Huang P, Staerkel G, Sneige N, et al. Fine-needle aspiration of pancreatic serous cystadenoma: cytologic features and diagnostic pitfalls. Cancer. 2006;108:239-249.
15. Lal A, Bourtsos EP, DeFrias DV, et al. Microcystic adenoma of the pancreas: clinical, radiologic, and cytologic features. Cancer. 2004; 102:288-294.
16. Albrejeen AM, Romagnuolo J, Perini R, et al. Utility of endoscopic ultrasound, cytology and fluid carcinoembryonic antigen and CA 19-9 levels in pancreatic cystic lesions. World J Gastroenterol. 2007;13:3962-3966.
17. Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126:1330-1336.
18. Moparty B, Logrono R, Nealon WH, et al. The role of endoscopic ultrasound and endoscopic ultrasound-guided fine-needle aspiration in distinguishing pancreatic cystic lesions. Diagn Cytopathol. 2007; 35:18-25.
19. Lewandrowski KB, Southern JF, Pins MR, et al. Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinomas. Ann Surg. 1993;217:41-47.
20. Linder JD, Geenen JE, Catalano MF. Cyst fluid analysis obtained by EUS-guided FNA in the evaluation of discrete cystic neoplasms of the pancreas: a prospective single-center experience. Gastrointest Endosc. 2006;64:697-702.
21. Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol. 2007;102:2339-2349.
22. Jimenez RE, Warshaw AL, Z'graggen K, et al. Sequential accumulation of KRAS mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg. 1999;230:501-509.
23. Z'graggen K, Rivera JA, Compton CC, et al. Prevalence of activating KRAS mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg. 1997;226:498-500.
24. Biankin AV, Biankin SA, Kench JG, et al. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumors of the pancreas is associated with invasive ductal adeno-carcinoma. Gut. 2002;50:861-868.
25. Iacobuzio-Donahue CA, Wilentz RE, Argani P, et al. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol. 2000;24:1544-1548.
26. Lapkus O, Gologan O, Liu Y, et al. Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. Mod Pathol. 2006;19:907-913.
27. Caldas C, Hahn SA, da Costa L, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8:27-32.
28. Shao J, Zhang L, Gao J, et al. Aberrant expression of PTCH (patched gene) and SMO (smoothened gene) in human pancreatic cancerous tissues and its association with hyperglycemia. Pancreas. 2006;33:38-44.
29. Furuya N, Kawa S, Akamatsu T, et al. Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice. Gastroenterology. 1997;113:593-598.
30. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:92ra66-92ra76.
31. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA. 2011;108:21188-21193.
32. Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc. 2009;69:1103-1105.
33. Shen J, Brugge WR, Dimaio CJ, et al. Molecular analysis of cyst fluid: a comparative analysis with current practice of diagnosis. Cancer. 2009;117:217-227.
34. Toll AD, Kowalski T, Loren D, et al. The added value of molecular testing in small pancreatic cysts. J Pancreas. 2010;11:582-586.